Verition Fund Management’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Verition Fund Management’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-30,004	Closed	-$11K	–	3328
2022 Q2	$11K	Buy	30,004 +4	+0%	+$3	﹤0.01%	2251
2022 Q1	$45K	Hold	30,000	–	–	﹤0.01%	2507
2021 Q4	$73K	Hold	30,000	–	–	﹤0.01%	2371
2021 Q3	$160K	Buy	+30,000	New	+$270K	﹤0.01%	1647

Other funds holding CRXT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Verition Fund Management's CRXT Position: Q3 2022 in Review

Verition Fund Management sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 30,004 shares — an estimated $11K sold.

Verition Fund Management first reported a position in CRXT in Q3 2021 and held it in 4 quarters. The position peaked at $160K in Q3 2021. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

Verition Fund Management reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Verition Fund Management sold 30,004 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $11K.
Verition Fund Management first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
Verition Fund Management's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $160K in Q3 2021.
2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Verition Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.